Bart A. Westerman

Dr. Bart A. Westerman

orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 October 2020 in Nucleic Acids Research
Verified
Journal Article
Open access
PDF file
GKGeorgi K Kanev
Georgi K Kanev
CGChris De Graaf
Chris De Graaf
BWBart A. Westerman
Bart A. Westerman
IEIwan de Esch
Iwan de Esch
AKAlbert Kooistra
Albert Kooistra
Kinases are a prime target of drug development efforts with >60 drug approvals in the past two decades. Due to the research into this protein family, a wealth of data has been accumulated that keeps on growing. KLIFS—Kinase–Ligand Interaction Fingerprints and Structures—is a structural database focusing on how kinase inhibitors interact with their targets. The aim of KLIFS is to support (structure-based) kinase research through the systematic collection, annotation, and processing of kinase structures. Now, 5 years after releasing the initial KLIFS website, the database has undergone a complete overhaul with a new website, new logo, and new functionalities. In this article, we start by looking back at how KLIFS has been used by the research community, followed by a description of the renewed KLIFS, and conclude with showcasing the functionalities of KLIFS. Major changes include the integration of approved drugs and inhibitors in clinical trials, extension of the coverage to atypical kinases, and a RESTful API for programmatic access. KLIFS is available at the new domain https://klifs.net.

22 May 2023 in Journal of Medicinal Chemistry
Verified
Journal Article
Open access
FCFleur M.G. Cornelissen
Fleur M.G. Cornelissen
GMGreta Markert
Greta Markert
GDGhislaine Deutsch
Ghislaine Deutsch
MAMaria Antonara
Maria Antonara
NFNoa Faaij
Noa Faaij
BWBart A. Westerman
Bart A. Westerman
The blood-brain barrier (BBB) represents a major obstacle to delivering drugs to the central nervous system (CNS), resulting in the lack of effective treatment for many CNS diseases including brain cancer. To accelerate CNS drug development, computational prediction models could save the time and effort needed for experimental evaluation. Here, we studied BBB permeability focusing on active transport (influx and efflux) as well as passive diffusion using previously published and self-curated data sets. We created prediction models based on physicochemical properties, molecular substructures, or their combination to understand which mechanisms contribute to BBB permeability. Our results show that features that predicted passive diffusion over membranes overlap with features that explain endothelial permeation of approved CNS-active drugs. We also identified physical properties and molecular substructures that positively or negatively predicted BBB transport. These findings provide guidance toward identifying BBB-permeable compounds by optimally matching physicochemical and molecular properties to BBB transport mechanisms.

1 November 2019 in Trends in Pharmacological Sciences
Verified
Journal Article
Open access
GKGeorgi K. Kanev
Georgi K. Kanev
CGChris de Graaf
Chris de Graaf
IEIwan J.P. de Esch
Iwan J.P. de Esch
RLRob Leurs
Rob Leurs
TWThomas Würdinger
Thomas Würdinger
AKAlbert Kooistra
Albert Kooistra
Kinases are attractive anticancer targets due to their central role in the growth, survival, and therapy resistance of tumor cells. This review explores the two primary kinase classes, the eukaryotic protein kinases (ePKs) and the atypical protein kinases (aPKs), and provides a structure-centered comparison of their sequences, structures, hydrophobic spines, mutation and SNP hotspots, and inhibitor interaction patterns. Despite the limited sequence similarity between these two classes, atypical kinases commonly share the archetypical kinase fold but lack conserved eukaryotic kinase motifs and possess altered hydrophobic spines. Furthermore, atypical kinase inhibitors explore only a limited number of binding modes both inside and outside the orthosteric binding site. The distribution of genetic variations in both classes shows multiple ways they can interfere with kinase inhibitor binding. This multilayered review provides a research framework bridging the eukaryotic and atypical kinase classes.

13 March 2018 in Journal of Extracellular Vesicles
Verified
Journal Article
Open access
JBJordi Berenguer
Jordi Berenguer
TLTonny Lagerweij
Tonny Lagerweij
XZXi Wen Zhao
Xi Wen Zhao
SDSophie Dusoswa
Sophie Dusoswa
PSPetra van der Stoop
Petra van der Stoop
TWThomas Wurdinger
Thomas Wurdinger
Cancer cells release extracellular vesicles (EVs) that contain functional biomolecules such as RNA and proteins. EVs are transferred to recipient cancer cells and can promote tumour progression and therapy resistance. Through RNAi screening, we identified a novel EV uptake mechanism involving a triple interaction between the chemokine receptor CCR8 on the cells, glycans exposed on EVs and the soluble ligand CCL18. This ligand acts as bridging molecule, connecting EVs to cancer cells. We show that glioblastoma EVs promote cell proliferation and resistance to the alkylating agent temozolomide (TMZ). Using in vitro and in vivo stem‐like glioblastoma models, we demonstrate that EV‐induced phenotypes are neutralised by a small molecule CCR8 inhibitor, R243. Interference with chemokine receptors may offer therapeutic opportunities against EV‐mediated cross‐talk in glioblastoma.

10 June 2020 in Nature Communications
Verified
Journal Article
Open access
PDF file
RNRavi S. Narayan
Ravi S. Narayan
PMPiet Molenaar
Piet Molenaar
JTJian Teng
Jian Teng
FCFleur M. G. Cornelissen
Fleur M. G. Cornelissen
IRIrene Roelofs
Irene Roelofs
BWBart A. Westerman
Bart A. Westerman
Personalized cancer treatments using combinations of drugs with a synergistic effect is attractive but proves to be highly challenging. Here we present an approach to uncover the efficacy of drug combinations based on the analysis of mono-drug effects. For this we used dose-response data from pharmacogenomic encyclopedias and represent these as a drug atlas. The drug atlas represents the relations between drug effects and allows to identify independent processes for which the tumor might be particularly vulnerable when attacked by two drugs. Our approach enables the prediction of combination-therapy which can be linked to tumor-driving mutations. By using this strategy, we can uncover potential effective drug combinations on a pan-cancer scale. Predicted synergies are provided and have been validated in glioblastoma, breast cancer, melanoma and leukemia mouse-models, resulting in therapeutic synergy in 75% of the tested models. This indicates that we can accurately predict effective drug combinations with translational value.

20 December 2023 in Cancer Research
Verified
Journal Article
Open access
PDF file
TMTathiane M. Malta
Tathiane M. Malta
TSThais S. Sabedot
Thais S. Sabedot
NMNatalia S. Morosini
Natalia S. Morosini
IDIndrani Datta
Indrani Datta
LGLuciano Garofano
Luciano Garofano
HNHoutan Noushmehr
Houtan Noushmehr
Tumor adaptation or selection is thought to underlie therapy resistance in glioma. To investigate longitudinal epigenetic evolution of gliomas in response to therapeutic pressure, we performed an epigenomic analysis of 132 matched initial and recurrent tumors from patients with IDH-wildtype (IDHwt) and IDH-mutant (IDHmut) glioma. IDHwt gliomas showed a stable epigenome over time with relatively low levels of global methylation. The epigenome of IDHmut gliomas showed initial high levels of genome-wide DNA methylation that was progressively reduced to levels similar to those of IDHwt tumors. Integration of epigenomics, gene expression, and functional genomics identified HOXD13 as a master regulator of IDHmut astrocytoma evolution. Furthermore, relapse of IDHmut tumors was accompanied by histologic progression that was associated with survival, as validated in an independent cohort. Finally, the initial cell composition of the tumor microenvironment varied between IDHwt and IDHmut tumors and changed differentially following treatment, suggesting increased neoangiogenesis and T-cell infiltration upon treatment of IDHmut gliomas. This study provides one of the largest cohorts of paired longitudinal glioma samples with epigenomic, transcriptomic, and genomic profiling and suggests that treatment of IDHmut glioma is associated with epigenomic evolution toward an IDHwt-like phenotype. Significance: Standard treatments are related to loss of DNA methylation in IDHmut glioma, resulting in epigenetic activation of genes associated with tumor progression and alterations in the microenvironment that resemble treatment-naïve IDHwt glioma.